Akèy › Kansè nan tete › North Carolina
Etid klinik pou Kansè nan tete nan North Carolina
90 etid pou Kansè nan tete ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
- Durham63 etid
- Charlotte22 etid
- Winston-Salem14 etid
- Concord5 etid
- Shelby5 etid
- Greensboro5 etid
- Gastonia4 etid
- High Point4 etid
- Greenville4 etid
- Asheville3 etid
- Raleigh3 etid
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07059884Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Duke Cancer Network, Durham
- Cone Health Cancer Center, Greensboro
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- ak 6 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Levine Cancer, Charlotte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07102381Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
- University of North Carolina, Chapel Hill
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 45 · Fanm · Mizajou Oct 1, 2026 · NCT05557877A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06369285Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07360314Radiation Therapy and Thymus Function in Young Women With Breast Cancer
- Duke Cancer Center, Durham
Ap rekriteEtid obsèvasyon
Laj 18 a 50 · Fanm · Mizajou Sep 29, 2026 · NCT07725172BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Duke Cancer Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06120283A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Novant Health Cancer Institute ( Site 0019), Charlotte
- Novant Health Oncology Specialists ( Site 0074), Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07060807Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
- University of North Carolina, Chapel Hill
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Sep 28, 2026 · NCT05440929Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
Ap rekrite
Laj 30 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT02945579A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Levine Cancer Institute ( Site 0014), Charlotte
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Levine Cancer Institute, Albemarle
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
- ak 11 plis
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06377852ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Duke Cancer Institute, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Charlotte
- Clinical Trial Site, Durham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Atrium Levine Cancer Institute, Charlotte
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Messino Cancer Centers, Asheville
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology, Cary
- University of North Carolina Medical Center, Chapel Hill
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of North Carolina Medical Center, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Atrium Health, Charlotte
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05894239Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07340541Identifying Patterns in the Breath of Individuals With Breast Cancer
- Duke University Medical Cente, Durham
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 74 · Fanm · Mizajou Sep 18, 2026 · NCT06512350ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Oncology Specialists of Charlotte Pa, Charlotte
- Carolina Oncology Specialists, Charlotte
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07173751Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07685938Utility of a Mobile Application for Young Women With Breast Cancer
- Atrium Health Levine Cancer, Charlotte
Ap rekrite
Laj 18 a 45 · Fanm · Mizajou Sep 15, 2026 · NCT07009093A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Duke Cancer Institute, Durham
- Cape Fear Valley Medical Center, Fayetteville
- Cone Health Cancer Center at Wesley Long, Greensboro
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- University of North Carolina at Chapel Hill, Chapel Hill
Ap rekriteEtid obsèvasyon
Laj 20 a 74 · Fanm · Mizajou Sep 14, 2026 · NCT07214610A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Charlotte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT05123482A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Duke Cancer Institute, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT03424005A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Duke Cancer Institute, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute, Charlotte
- Novant Health Oncology Specialists, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07100106Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Duke Cancer Institute, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT05315700Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
- University of North Carolina, Chapel Hill
Ap rekriteFaz 2
Laj 50 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06902311Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Duke University, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT05846789A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Novant Health Cancer Institute, Charlotte
- Duke Cancer Institute, Durham
- Novant Health Cancer Institute, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06790693Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07025785The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- ak 47 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.